Assessment of the Efficacy of <i>Withania somnifera</i> Root Extract in Patients with Generalized Anxiety Disorder: A Randomized Double-blind Placebo- Controlled Trial
Fuladi S, Emami SA, Mohammadpour AH, Karimani A, Manteghi AA, Sahebkar A
Current reviews in clinical and experimental pharmacology · 20 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2020-04-13 · Curr Rev Clin Exp Pharmacol · vol. 16 · número 2 · págs. 191–196
- Editorial
- Bentham Science Publishers
- Citado
- 33 citas · más que el 94% de estudios similares · 4.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes · Medicinal Plant Extracts Effects
- Palabras clave
- Generalized anxiety disorder, Withania somnifera, Discontinuation, Placebo, Randomized controlled trial, Medicine, Hamilton Anxiety Rating Scale, Anxiety, Anxiolytic, Population, Psychiatry, Internal medicine, Pathology, Alternative medicine
- MeSH
- humans, withania, anti-anxiety agents, plant extracts, anxiety disorders, iran
6 autores
- Sara Fuladi🇮🇷Mashhad University of Medical Sciences
- Seyed Ahmad Emami🇮🇷Mashhad University of Medical Sciences
- Amir Hooshang Mohammadpour🇮🇷Mashhad University of Medical Sciences
- Asieh Karimani🇮🇷Mashhad University of Medical Sciences
- Ali Akhondpour Manteghi🇮🇷 · autor de correspondenciaMashhad University of Medical Sciences
- Amirhossein Sahebkar🇮🇷Mashhad University of Medical Sciences; Biotechnology Research Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Anxiety disorders are the most universal psychiatric problems in the general population. Due to their chronic nature, these diseases are managed with a multi-drug regimen lasting for a long period of time. Medication discontinuation leads to 25% and 80% recurrence in the first month and the first year, respectively. Despite several treatment approaches, there is no specific and optimal method for patient management. Therefore, it is necessary to find some new therapeutic approaches with fewer side effects. Withania somnifera is a plant with GABAergic property responsible for its anxiolytic effect. The aim of this study was to investigate the effect of W. somnifera root extract as an alternative therapy to reduce standard Generalized Anxiety Disorder (GAD) symptoms.
Methods
Forty patients who met the inclusion criteria (with a confirmed diagnosis of GAD as stated in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) took part in this randomized double-blind placebo-controlled trial and were randomly selected for participation in the treatment group (W. somnifera extract, 1g/day; n = 22) or the placebo group (n = 18). All patients were under treatment with Selective Serotonin Reuptake Inhibitors (SSRIs) and were prescribed one capsule of the extract or placebo per day for six weeks. The Hamilton anxiety rating scale (HAM-A) was used to assess the severity of GAD symptoms at baseline as well as the second and sixth weeks of the trial.
Results
Comparison of the HAM-A scores during the course of the trial revealed a significant amelioration ofHAM-A score in the treatment group versus placebo (14 and 8 units reduction, respectively (P < 0.05)). Moreover, there was a significant difference in the reduction of GAD score between the second (P =0.04) and sixth week (P =0.02) in the treatment group. The extract was safe and no adverse effect was observed during the trial.
Conclusion
W. somnifera extract offers some potential advantages as a safe and effective adjunctive therapy to SSRIs in GAD. The clinical trial protocol has been registered under the Iranian Registry of Clinical Trials (IRCT20180615040105N1).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.